Request More Information

Change: Change(%):
Volume: Open:
High: Low:
52Wk High: 52Wk Low:

Experts Commenting on This Company


Visit Company Website

View Company News

StemCells Inc.


StemCells Inc. is engaged in the research and development of cell-based therapeutics. The company's proprietary HuCNS-SC cells (purified human neural stem cells) are currently in development as a potential treatment for a broad range of central nervous system disorders. The company is currently conducting phase 1/2 clinical trials in chronic spinal cord injury and dry age-related macular degeneration. StemCells Inc. is also pursuing preclinical studies in Alzheimer's disease, with support from the California Institute for Regenerative Medicine. The company markets stem cell research products, including media and reagents, under the SC Proven brand.

The information provided below is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.

Expert Comments:

Stephen Dunn, LifeTech Capital (3/24/14) "We are reiterating a Strong Buy with a price target of $4.50 as StemCells Inc. continues to be one of the most advanced players in the stem cell space. . .the company is now progressing with controlled phase 2 trials in cervical spinal cord injury and dry age-related macular degeneration, and it is also expecting to file an investigational new drug application for Alzheimer's disease a year early in 2016."

Keay Nakae, Ascendiant Capital Markets (3/13/14) "The pace of enrollment in StemCells Inc.'s two phase 1/2 clinical studies has picked up, benefitting from the addition of more clinical sites. . .as we near completion of enrollment in its two current clinical studies, investors will soon have additional human clinical data, which could further support our investment thesis."

Jason Kolbert, Maxim Group (3/13/14) "StemCells Inc. received authorization from Health Canada to expand the phase 1/2 clinical trial for spinal cord injury (SCI) into Canada. . .we also note that the company received U.S. Food and Drug Administration authorization to begin U.S. clinical testing in SCI. . .we look forward to a more rapid enrollment in 2014 as the company moves toward bigger patient numbers and more definitive point-of-care data."

Stephen Dunn, LifeTech Capital (1/10/14) "StemCells Inc.'s HuCNS-SC (purified human neural stem cells) have shown unprecedented results in human patients for Pelizaeus-Merzbacher disease and for complete thoracic spinal cord Injury, and both programs are continuing to progress. In addition, the dry age-related macular degeneration trial is progressing with additional trial sites. California Institute for Regenerative Medicine's $19M funding for HuCNS-SC in Alzheimer's disease validates the company's research, demonstrating for the first time that human neural stem cells can have a significant effect on memory in two different animal models."

Ling Wang, Chardan Capital Markets (1/10/14) "StemCells Inc. has announced that the HuCNS-SC phase 1/2 spinal cord injury trial expanded enrollment in North America. . .we reiterate our Buy rating. . .with two phase 1/2 trials to report data in 2014, the planned initiation of two definitive proof-of-concept efficacy trials in 2014 and a healthy balance sheet, we believe the company's shares are currently significantly undervalued."

more comments

Stephen Dunn, LifeTech Capital (1/2/14) "StemCells Inc. begins 2014 with a very strong balance of over $30M cash, which enables the company Inc. to continue developing its HuCNS-SC cells (purified human neural stem cells) for multiple indications uninterrupted. . .StemCells Inc. continues to be one of the most advanced players in the stem cell space. . .the company's strong management team and strong science continues to be successfully validated."

The Life Sciences Report Interview with Jason Kolbert (5/10/13) "StemCells Inc. operates at the next level of cell therapy. When I talk about mesenchymal cells and the trophic effects, it's exciting. But when I talk about potentially pluripotent cells and the ability for cells to remyelinate a demyelinating disorder like Batten disease, or to impact dry macular degeneration, or to impact the outcome in spinal paralysis. . .we're talking about the next level of science.

While it's been painstakingly meticulous, with the science and evolution of the field taking a long time, the way that StemCells is going about its clinical trials and developing its product and its cell line has been brilliant. I think it is a true leader in the field. When we look central nervous system disorders, we should look at companies like StemCells—and the way it is accomplishing its science—as the right way to do things. . .this company is doing pioneering work." More >

Jason Kolbert, Maxim Group (1/8/13) "StemCells Inc.'s spine cord trial has now officially been expanded to the U.S. and Canada. . .we expect to see this trial transition to a phase 2 study by mid 2014. We also believe that this indication [as well as age-related macular degeneration (AMD) and Pelizaeus-Merzbacher disease (PMD)] may qualify for breakthrough designation, resulting in an accelerated pathway to the marketplace. . .we expect the dry AMD trial to complete enrollment by mid-2014. . .the number of clinical sites has now been expanded to five. The dry AMD market is approximately 10x the wet AMD market. As such, point-of-care data from this trial has the potential to be transformative for the company. . .the market opportunities in spine and AMD are large and totally unmet."

fewer comments
Due to permission requirements, not all quotes are shown.

StemCells Inc. Content

Back to Top

Would you like additional information on Regenerative Medicine companies?